Reply
Feng Su, George N. Ioannou – 18 January 2017
Race or genetic makeup for hepatitis C virus treatment decisions?
Thomas R. O'Brien, Shyam Kottilil, Jordan J. Feld, Timothy R. Morgan, Ruth M. Pfeiffer – 18 January 2017
The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis
Zongwen Shuai, Jinjun Wang, Madhu Badamagunta, Jinjung Choi, Guoxiang Yang, Weici Zhang, Thomas P. Kenny, Kathryn Guggenheim, Mark J. Kurth, Aftab A. Ansari, John Voss, Ross L. Coppel, Pietro Invernizzi, Patrick S.C. Leung, M. Eric Gershwin – 18 January 2017 – The identification of environmental factors that lead to loss of tolerance has been coined the holy grail of autoimmunity.
A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis
Càndid Villanueva, Isabel Graupera, Carles Aracil, Edilmar Alvarado, Josep Miñana, Ángela Puente, Virginia Hernandez‐Gea, Alba Ardevol, Oana Pavel, Alan Colomo, Mar Concepción, María Poca, Xavier Torras, Josep M. Reñe, Carlos Guarner – 18 January 2017 – Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifies the risk of variceal rebleeding (VRB). We assessed whether guiding therapy with hepatic venous pressure gradient (HVPG) monitoring may improve survival by preventing VRB.
Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review
Veeral H. Ajmera, Norah A. Terrault, Stephen A. Harrison – 18 January 2017 – Moderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet the effects on cardiovascular and liver health are unclear. Moderate alcohol use is associated with improved insulin sensitivity and decreased cardiovascular mortality in the general population, but whether similar benefits would be observed in persons with NAFLD remains largely unstudied.
What is the benefit of early follow‐up after hospitalization for patients with cirrhosis?
Robert Driver, Ian A. Rowe – 18 January 2017
Primary biliary cholangitis: Treatment options finally expand
Cynthia Levy – 17 January 2017
The dynamic landscape of liver transplant in the era of effective hepatitis C virus therapy
Elizabeth C. Verna – 17 January 2017
Reply
David S. Goldberg – 17 January 2017
An endoplasmic reticulum protein, Nogo‐B, facilitates alcoholic liver disease through regulation of kupffer cell polarization
Jin‐Kyu Park, Mingjie Shao, Moon Young Kim, Soon Koo Baik, Mee Yon Cho, Teruo Utsumi, Ayano Satoh, Xinsho Ouyang, Chuhan Chung, Yasuko Iwakiri – 16 January 2017 – Nogo‐B (Reticulon 4B) is an endoplasmic reticulum (ER) resident protein that regulates ER structure and function. Because ER stress is known to induce M2 macrophage polarization, we examined whether Nogo‐B regulates M1/M2 polarization of Kupffer cells and alters the pathogenesis of alcoholic liver disease (ALD).